Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 7/20 | 0.57 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.57 |
| ▸ | NAT1 | P18440 | 4/20 | 0.56 |
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | MAX | P61244 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090249 | 1.00 | MEN1 (0.60) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL885537 | 1.00 | MEN1 (0.60) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL2421824 | 0.87 | PIM1 (0.74) | MEN1KMT2ALMNAHPGDPKM | |
| SCHEMBL2421827 | 0.87 | PIM1 (0.74) | MEN1KMT2ALMNAHPGDPKM | |
| SCHEMBL2065291 | 0.85 | NAT1 (0.60) | MEN1KMT2APIM1PIM3PIM2 | |
| SCHEMBL10090250 | 0.85 | NAT1 (0.60) | MEN1KMT2APIM1PIM3PIM2 | |
| SCHEMBL2065290 | 0.85 | NAT1 (0.60) | MEN1KMT2APIM1PIM3PIM2 | |
| SCHEMBL10090252 | 0.83 | PTP4A3 (0.60) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL2066683 | 0.83 | PTP4A3 (0.60) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL2066680 | 0.83 | PTP4A3 (0.60) | MEN1KMT2APOLBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | claimed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | claimed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | MEN1 4202/4885KMT2A 2746/4885POLB 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.